Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A US health panel advises starting mammograms at age 40 rather than 50.

2.

Infection Burden High With Myeloma T-Cell Therapies

3.

Study opens up possibility of bespoke prostate cancer treatment

4.

There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.

5.

How Much of a Cancer Drug Is Too Much?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot